Drug Profile
Research programme: JAK2 inhibitors - Astex Therapeutics
Latest Information Update: 25 Jul 2011
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Class
- Mechanism of Action Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
- 24 Oct 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
- 29 May 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)